The sodium phenylbutyrate market comprises drugs that are used for the management of urea cycle disorders (UCDs). Sodium phenylbutyrate has shown efficacy in controlling hyperammonemia associated with UCDs and is typically administered as initial therapy along with dietary protein restriction and amino acid supplementation. Commonly prescribed brand names of sodium phenylbutyrate include Buphenyl and Ammonaps.
The global sodium phenylbutyrate market is estimated to be valued at US$ 2.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the sodium phenylbutyrate market include Halliburton Co., Hifi Engineering Inc., Silixa Ltd., Schlumberger Limited, Banweaver, Omnisens SA, Future Fibre Technologies Ltd., Baker Hughes, Inc., Qintiq Group PLC, and Fotech Solutions Ltd. These players are focusing on new product launches and geographical expansion to strengthen their market position.
The growing prevalence of UCDs globally is a major factor driving the demand for sodium phenylbutyrate drugs. According to estimates, UCDs affect around 1 in 35,000 newborns worldwide. However, the availability of generic equivalents of branded drugs is a major challenge for market players.
The market is witnessing significant growth in regions such as North America, Europe, and Asia Pacific. Key players are investing in these regions to tap the potential available from the increasing healthcare expenditures and demand for advanced UCD treatment therapies.
Market Key Trends
One of the key trends witnessed in the global sodium phenylbutyrate market is the rising focus of pharmaceutical companies on the development of new delivery systems to improve the efficacy and tolerability of sodium phenylbutyrate drugs. Research is ongoing on the development of controlled-release formulations as well as formulations compatible with enteral feeding tubes. This is anticipated to boost therapy adherence over the forecast period.
Porter’s Analysis
Threat of new entrants: Entering the Sodium Phenylbutyrate Market Growth is not an easy task due to high capital requirements and established player presence. Bargaining power of buyers: Large buyers can negotiate for low prices from suppliers due to their high purchase volumes but substitutes availability limits this power. Bargaining power of suppliers: A few suppliers have dominance in sodium phenylbutyrate manufacturing which gives them stronger bargaining power against buyers. Threat of new substitutes: Development of alternative treatment options poses a mild threat especially for conditions where sodium phenylbutyrate is not the only treatment option. Competitive rivalry: Established players compete on the basis of product quality, reliability of supply and expanding into new application areas.
The North America region currently holds the major share of the global sodium phenylbutyrate market in terms of value owing to high prevalence of urea cycle disorders in the region along with developed healthcare infrastructure and availability of reimbursement. Another major geographical region is Europe due to growing demand for orphan drugs and increasing research & development activities in the pharmaceutical industry.
The Asia Pacific region is poised to witness the highest growth in the sodium phenylbutyrate market during the forecast period. This is attributed to fast development of healthcare facilities, rising disposable incomes, growing awareness about rare diseases and their treatment options in developing countries such as India and China.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it